文献速递炎症性肠病消化内镜

胶囊内镜用于克罗恩病达标治疗监测:系统综述与荟萃分析

Capsule endoscopy for treat-to-target monitoring in Crohn's disease: a systematic review and meta-analysis.
PubMed 文献 · Gastrointest Endosc · 2026-06-25

该系统综述与荟萃分析纳入9项研究共321例小肠或回结肠型克罗恩病患者,评估小肠胶囊内镜(SBCE)和全消化道胶囊内镜(PCE)在达标治疗策略中的作用。基线时76.3%患者存在活动性疾病,71%患者据此调整治疗,活动性疾病患者中93%调整治疗。加权平均随访33.5周后,黏膜愈合的合并比例为27%(95%CI 18%-38%),异质性显著(I2=71%)。

要点

  • 胶囊内镜可全面评估黏膜活动并支持达标治疗下的个体化治疗优化。
  • 基线活动性疾病检出率76.3%,71%患者据此调整治疗。
  • 随访33.5周后黏膜愈合合并比例27%(95%CI 18%-38%)。

核心结论

  • 胶囊内镜支持在达标治疗策略中主动、个体化地优化治疗。
  • 需进一步前瞻性研究标准化结局定义并明确其对长期临床结局的影响。

研究设计与样本

  • 纳入使用胶囊内镜监测黏膜活动并指导治疗的随机临床试验和观察性研究。
  • 共纳入9项研究、321例患者,加权平均年龄31.3岁,46%为男性。
  • 主要结局为目标药物治疗后达到黏膜愈合的患者比例,采用随机效应模型估计合并比例,I2统计量评估异质性。

主要发现

  • 基线时76.3%患者检出活动性疾病。
  • 总体71%患者调整治疗,活动性疾病患者中93%调整治疗。
  • 加权平均随访33.5周后,黏膜愈合合并比例为27%(95%CI 18%-38%),异质性显著(I2=71%)。
  • 43%患者观察到黏膜应答,34%患者无应答。
  • 胶囊滞留发生1例。

临床怎么用

  • 胶囊内镜(SBCE或PCE)可用于小肠或回结肠型克罗恩病达标治疗策略中的黏膜活动监测。
  • 胶囊内镜检出活动性疾病后可据此调整治疗,以实现个体化治疗优化。

局限性

  • 纳入研究间异质性显著(I2=71%)。
  • 需进一步前瞻性研究标准化结局定义并明确对长期临床结局的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Achieving mucosal healing has become a central therapeutic objective in treat-to-target strategies for Crohn's disease (CD). Capsule endoscopy, including small-bowel capsule endoscopy (SBCE) and pan-enteric capsule endoscopy (PCE), enables comprehensive mucosal evaluation and supports treatment optimization. This systematic review and meta-analysis aimed to evaluate the role of SBCE and PCE within treat-to-target strategies in patients with small-bowel or ileocolonic CD. METHODS: A systematic search of PubMed/MEDLINE, Cochrane Central Register of Controlled Trials, ClinicalTrials.gov, and Google Scholar was conducted from inception to November 2025. Randomized clinical trials and observational studies using capsule endoscopy to monitor mucosal activity and guide therapy were included. The primary outcome was the proportion of patients achieving mucosal healing after targeted medical therapy. Pooled proportions were estimated using random-effects models, and heterogeneity was assessed using the I2 statistic. RESULTS: Nine studies comprising 321 patients were included. The weighted mean age was 31.3 years, and 46% of patients were male. Active disease was detected in 76.3% of patients at baseline, leading to treatment modification in 71% overall and in 93% of patients with active disease. After a weighted mean follow-up of 33.5 weeks, the pooled proportion of patients achieving mucosal healing was 27% (95% CI, 18%-38%), with substantial heterogeneity (I2 = 71%). Mucosal response was observed in 43% of patients, whereas 34% showed no response. Capsule retention was observed in 1 case. CONCLUSIONS: Capsule endoscopy enables comprehensive assessment of mucosal activity across the GI tract and supports proactive, individualized treatment optimization within treat-to-target strategies. Further prospective studies are needed to standardize outcome definitions and to clarify their impact on long-term clinical outcomes.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Marmo C, Puca FS, McNamara D, et al. Capsule endoscopy for treat-to-target monitoring in Crohn's disease: a systematic review and meta-analysis. Gastrointest Endosc. 2026. PMID: 42349762. doi:10.1016/j.gie.2026.06.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。